Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21767539 | 1.00 | GAA (0.46) | GAAHTTAPPKDM4EALDH1A1 | |
| SCHEMBL26050204 | 0.78 | ALDH1A1 (0.32) | GAAHTTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL18031328 | 0.78 | APP (0.37) | GAAHTTAPPKDM4EALDH1A1 | |
| SCHEMBL20241485 | 0.77 | ERN1 (0.43) | GAAKDM4EALDH1A1NFE2L2 | |
| SCHEMBL30682148 | 0.77 | ERN1 (0.43) | GAAKDM4EALDH1A1NFE2L2 | |
| SCHEMBL22759820 | 0.76 | HSP90AA1 (0.33) | HTTAPPKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1877387 | 0.74 | ABCG2 (0.68) | GAAHTTAPPKDM4EALDH1A1 | |
| SCHEMBL1877390 | 0.74 | ABCG2 (0.68) | GAAHTTAPPKDM4EALDH1A1 | |
| SCHEMBL20241484 | 0.73 | KDM4E (0.43) | GAAHTTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30149898 | 0.73 | KDM4E (0.43) | GAAHTTKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459942-B2 | Inhibiting (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20240376095-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | SCHR¿DINGER, LLC | 2024-11-14 | — | — | US | disclosed |
| US-11739087-B2 | Inhibiting (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739087-B2 | Inhibiting (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| EP-4086254-A1 | INTEGRIN INHIBITORS | Morphic Therapeutic, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| US-20220073511-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2022-03-10 | — | — | US | disclosed |
| US-11021480-B2 | Inhibiting (α-V)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200385384-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | SCHRÖDINGER, LLC | 2020-12-10 | — | — | US | disclosed |
| US-20200354359-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-11-12 | — | — | US | disclosed |
| WO-2020047239-A1 | INHIBITING αV β6 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| US-20200071322-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-03-05 | — | — | US | disclosed |
| EP-3617206-A1 | INTEGRIN INHIBITORS | Morphic Therapeutic, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459942-B2 | Inhibiting (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | GAA 333/4885HTT 3998/4885APP 2366/4885 |
| US-20220073511-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | GAA 362/4885HTT 4086/4885APP 2180/4885 |
| US-20200071322-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | GAA 362/4885HTT 4086/4885APP 2180/4885 |
| US-20240376095-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | GAA 362/4885HTT 4086/4885APP 2180/4885 |
| US-20200354359-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | GAA 362/4885HTT 4086/4885APP 2180/4885 |
| US-20200385384-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | GAA 362/4885HTT 4086/4885APP 2180/4885 |
| US-11021480-B2 | Inhibiting (α-V)(β-6) integrin | ITGB6, ITGA6, ITGAV | GAA 333/4885HTT 3998/4885APP 2366/4885 |
| US-11739087-B2 | Inhibiting (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | GAA 333/4885HTT 3998/4885APP 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.